gastroparesis and glp 1 drugs Lawsuits involving popular GLP-1 medications such as Ozempic, Wegovy, Mounjaro continue to grow as patients report serious side effects, including gastroparesis, severe gastrointestinal complications, and NAION vision loss. These medications, widely A wrongful-death lawsuit alleges Novo

Published research indicates that simultaneous activation creates a synergistic effect distinct from mono or dual-agonism

Patients using GLP-1 medications had twice the risk of developing vision-threatening nAMD compared with those not taking these drugs

Effects of lixisenatide once daily on gastric emptying in type 2 diabetesrelationship to postprandial glycemia

Eisenberg oversaw the project, providing critical feedback and revisions to the manuscript

Compounded versions of semaglutide and tirzepatide have emerged as lower-cost alternatives through compounding pharmacies, though their regulatory status has been evolving

Tirzepatide, used in Zepbound and Mounjaro, targets both the GLP-1 and the GIP receptor agonist, while semaglutide, found in Wegovy and Ozempic, mimics only the GLP-1 receptor agonist, a type of hormone in the body that impacts everything from the brain to muscle to the pancreas, stomach and liver